



HE Dr. Talantbek Batyraliev
The Minister of Health
Ministry of Health
Moskovskaya Str. 148
720040 Bishkek
The Republic of Kyrgyzstan

14 December 2016

Decision Letter: Request for 2017 Renewal of Gavi vaccine support

Your Excellency,

I am writing in relation to Kyrgyzstan's request for renewal of the New Vaccine Support (NVS) for Pneumococcal Vaccine, Pentavalent Vaccine and support for Health Systems Strengthening that was reviewed by Gavi Managing Directors' Review on 18 of October 2016.

Following the recommendations made by the Managing Directors' Review, I am pleased to inform you that Gavi has **approved** Kyrgyzstan's request to renew Gavi support vaccines for 2017, subject to several conditions and requirements as specified in the Appendices to this letter.

The Appendices include the following important information:

- Appendix A: Financial and Programmatic information –Support for Pneumococcal Vaccine (PCV)
- Appendix B: Financial and Programmatic information –Support for Pentavalent Vaccine
- Appendix C: Financial and Programmatic information –Support for Injection Safety Devices
- Appendix D: Recommendations of the Managing Directors' Review

Please do not hesitate to contact my colleague Ms Nilgun Aydogan at naydogan@gavi.org if you have any questions or concerns.

Yours sincerely,

Hind Khatib-Othman
Managing Director, Country Programmes

cc: The Minister of Finance
The Director of Medical Services
Director Planning Unit, MoH
The EPI Manager
WHO Country Representative
UNICEF Country Representative
Regional Working Group
WHO HQ



UNICEF Programme Division
UNICEF Supply Division

**Decision Letter
Kyrgyzstan - Support for Pneumococcal Vaccine**

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: The Republic of Kyrgyzstan			
2. Grant number: 17-KGZ-12c-X			
3. Date of Decision Letter: 14/12/2016			
4. Date of the Partnership Framework Agreement: 19/05/2014			
5. Programme title: New Vaccine Support (NVS), Pneumococcal Routine			
6. Vaccine type: Pneumococcal			
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose(s) per vial , LIQUID			
8. Programme duration¹: 2015 - 2017			
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)			
	2015-2016	2017	Total²
Programme Budget (US\$)	2,852,952 ³	2,006,500	4,859,452
10. Vaccine introduction grant (in US\$): . Not applicable.			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴			
Type of supplies to be purchased with Gavi funds in each year	2015-2016	2017	
Number of Pneumococcal vaccines doses		530,800	
Annual Amounts (US\$)	US\$2,852,952 ⁵	US\$2,006,500	
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
13. Self-procurement: Not applicable.			
14. Co-financing obligations: Reference code: 17-KGZ-12c-X-C According to the co-financing policy, the Country falls within the group Preparatory transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.			
Type of supplies to be purchased with Country funds in each year	2017		
Number of vaccine doses	80,100		
Number of AD syringes	84,700		
Number of safety boxes	950		
Value of vaccine doses (US\$)	US\$264,160		
Total co-financing payments (US\$) (including freight)	US\$281,000		
15. Operational support for campaigns: Not applicable			
16. Additional reporting requirements: Not applicable			

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
17. Financial clarifications: Not applicable.	
18. Other conditions: Not applicable.	

Signed by,



On behalf of Gavi
 Hind Khatib-Othman
 Managing Director, Country Programmes
 14 December 2016

Decision Letter
Kyrgyzstan - Support for Pentavalent Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: The Republic of Kyrgyzstan			
2. Grant number: 17-KGZ-04a-X			
3. Date of Decision Letter: 14/12/2016			
4. Date of the Partnership Framework Agreement: 19/05/2014			
5. Programme title: New Vaccine Support (NVS), Pentavalent Routine			
6. Vaccine type: Pentavalent			
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 1 dose(s) per vial, LIQUID			
8. Programme duration⁶: 2009 - 2017			
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)			
	2009-2016	2017	Total⁷
Programme Budget (US\$)	8,592,971 ⁸	851,500	9,444,471
10. Vaccine introduction grant (in US\$): . Not applicable			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁹			
Type of supplies to be purchased with Gavi funds in each year	2009-2016	2017	
Number of Pentavalent vaccines doses		461,500	
Annual Amounts (US\$)	US\$8,592,971¹⁰	US\$851,500	
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
13. Self-procurement: Not applicable.			
14. Co-financing obligations: Reference code: 17-KGZ-04a-X-C According to the co-financing policy, the Country falls within the group Preparatory transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.			
Type of supplies to be purchased with Country funds in each year	2017		
Number of vaccine doses	70,100		
Number of AD syringes	73,700		
Number of safety boxes	825		
Value of vaccine doses (US\$)	US\$124,333		
Total co-financing payments (US\$) (including freight)	US\$133,000		
15. Operational support for campaigns: Not applicable			
16. Additional reporting requirements: Not applicable			
Reports and other information	Due dates		
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated,	May		

⁶ This is the entire duration of the Programme.

⁷ This is the total amount endorsed by Gavi for the entire duration of the Programme.


⁸ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁹ This is the amount that Gavi has approved.

¹⁰ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
17. Financial clarifications: Not applicable.	
18. Other conditions: Not applicable.	

Signed by,



On behalf of Gavi
 Hind Khatib-Othman
 Managing Director, Country Programmes
 14 December 2016

**Decision Letter
Kyrgyzstan - Support for Injection safety devices**

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: The Republic of Kyrgyzstan		
2. Grant number: 17-KGZ-32a-X		
3. Date of Decision Letter: 14/12/2016		
4. Date of the Partnership Framework Agreement: 19/05/2014		
5. Programme title: Injection safety devices ¹¹		
6. Programme duration¹²: 2017		
7. Programme Budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)		
	2017	Total¹³
Programme Budget (US\$)	57,500	57,500
8. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ¹⁴		
TOTAL immunisation supplies to be purchased with Gavi funds in each year		2017
Number of AD syringes		1,127,700
Number of safety boxes		12,450
Annual Amounts for immunisation supplies for all Gavi vaccines (US\$)		57,500
Immunisation supplies to be purchased with Gavi funds in each year, by type of support		
New Vaccine Support (NVS), Pneumococcal (PCV13), 1 dose(s) per vial LIQUID,Routine		2017
Number of AD syringes		561,600
Number of safety boxes		6,200
Annual Amounts for immunisation supplies for Vaccine (US\$)		28,500
New Vaccine Support (NVS), DTP-HepB-Hib, 1 dose(s) per vial, LIQUID		2017
Number of AD syringes		485,400
Number of safety boxes		5,350
Annual Amounts for immunisation supplies for Vaccine (US\$)		24,500
New Vaccine Support (NVS), Inactivated Polio Vaccine, 1 dose(s) per vial, LIQUID,Routine		2017
Number of AD syringes		80,700
Number of safety boxes		900
Annual Amounts for immunisation supplies for Vaccine (US\$)		4,500
9. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.		
10. Self-procurement: Not application.		
11. Co-financing obligations: Co-financing requirements are listed in the relevant vaccine Decision Letter.		

¹¹ This does not include vaccines.

¹² This is the entire duration of the Programme.

¹³ This is the total amount endorsed by Gavi for the entire duration of the Programme.

¹⁴ This is the amount that Gavi has approved.



Signed by,

Hind H. Khatib

On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

14 December 2016

The MDs, following their deliberations:

- Recommended to the CEO:

Programme	Recommendation	Period	Indicative amount to be paid by Gavi
NVS – <i>PCV</i> in existing presentation	Extension	2017	US\$ 2,006,500
NVS – <i>Penta</i> in existing presentation	Extension	2017	US\$ 851,500

- Indicated that the disbursement of the 2nd tranche of the HSS grant is subject to the proof that the funds can actually be accessed and spent effectively on HSS activities.

